SCHEMBL7570972

SCHEMBL7570972

O=C(O)c1cc(COC(Cn2ccnc2)c2ccc(F)cc2)ccc1CCc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.49
PTGS2 P35354 1/20 0.45
CYP3A4 P08684 5/20 0.45
TDP1 Q9NUW8 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
CYP1A2 P05177 3/20 0.45
CYP2C9 P11712 3/20 0.45
MEN1 O00255 3/20 0.45
TSHR P16473 3/20 0.45
KMT2A Q03164 3/20 0.45
TRPM8 Q7Z2W7 2/20 0.45
TP53 P04637 2/20 0.45
MAPK1 P28482 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HSD17B10 Q99714 1/20 0.45
ORAI1 Q96D31 2/20 0.44
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
NPY2R P49146 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7564052 0.93 IDO1 (0.49) IDO1PTGS2CYP3A4TDP1ALDH1A1
SCHEMBL7563951 0.88 PTGS2 (0.46) IDO1PTGS2CYP3A4TDP1ALDH1A1
SCHEMBL7563092 0.84 PTGS2 (0.52) IDO1PTGS2CYP3A4TDP1ALDH1A1
SCHEMBL7564412 0.83 FNTA (0.49) IDO1PTGS2
SCHEMBL9996124 0.82 IDO1 (0.60) IDO1CYP3A4TDP1ALDH1A1MAPT
SCHEMBL7570978 0.80 CYP19A1 (0.45) CYP3A4TDP1ALDH1A1MAPTCYP1A2
SCHEMBL7561955 0.78 FNTA (0.51) IDO1PTGS2CYP3A4CYP2C9CYP2D6
SCHEMBL7568488 0.78 PTGS2 (0.40) IDO1PTGS2CYP3A4TDP1ALDH1A1
SCHEMBL7561297 0.77 TBXAS1 (0.38) IDO1PTGS2CYP3A4TDP1ALDH1A1
SCHEMBL7568524 0.76 PTGS2 (0.50) IDO1PTGS2CYP3A4TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-16 US disclosed
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-02 US disclosed
US-6342765-B1 COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS ASTRAZENECA UK LIMITED (GB) 2002-01-29 US disclosed
EP-1025088-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ASTRAZENECA AB (SE) 2001-09-05 EP disclosed
EP-1025088-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS AstraZeneca UK Limited (GB) 2000-08-09 EP disclosed
WO-1999020611-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ZENECA LIMITED (GB) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA IDO1 2422/4885PTGS2 2714/4885CYP3A4 307/4885
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA IDO1 2367/4885PTGS2 2763/4885CYP3A4 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.